CBG Shows Neuroprotective Promise in Alzheimer's Disease Preclinical Models

Two independent research groups — one at the Salk Institute for Biological Studies and one at the University of Bonn — published preclinical studies in January 2026 demonstrating that cannabigerol (CBG) has significant neuroprotective activity in Alzheimer's disease mouse models. The convergent findings from independent laboratories substantially strengthen the case for CBG as a candidate for human Alzheimer's disease trials.

The Salk Institute Study

The Salk Institute study, published in Nature Neuroscience, used the 5xFAD transgenic mouse model — one of the most aggressive and widely validated Alzheimer's disease models. Mice received CBG (10 mg/kg/day) or vehicle for 12 weeks beginning at 4 months of age, before significant plaque accumulation occurs.

CBG-treated mice showed a 41% reduction in amyloid-beta plaque burden in the hippocampus and cortex compared to vehicle-treated controls. Neuroinflammation markers — GFAP (astrocyte activation) and Iba-1 (microglial activation) — were reduced by 38% and 44% respectively. Cognitive testing using the Morris Water Maze and Novel Object Recognition tasks showed significantly better performance in CBG-treated mice, with performance approaching that of wild-type (non-transgenic) controls.

The University of Bonn Study

The University of Bonn study, published concurrently in Brain, used the APP/PS1 mouse model and focused on the mechanism of CBG's neuroprotective effects. The researchers identified that CBG's primary mechanism in Alzheimer's models is PPARγ (peroxisome proliferator-activated receptor gamma) activation, which reduces neuroinflammation and promotes amyloid-beta clearance through upregulation of the ABCA1 cholesterol transporter — a pathway that has been independently validated as relevant to Alzheimer's disease pathology.

Critically, the Bonn team demonstrated that CBG's neuroprotective effects were abolished by a PPARγ antagonist, confirming that PPARγ activation is the primary mechanism rather than CB1 or CB2 receptor activity.

Why CBG May Have Advantages Over CBD

Both CBD and CBG activate PPARγ, but the Salk study included a direct comparison arm and found CBG produced significantly greater plaque reduction than an equivalent dose of CBD. The researchers hypothesized that CBG's higher PPARγ binding affinity and its additional activity at the TRPA1 channel — which modulates neuroinflammation — may explain its superior efficacy in this model.

Path to Human Trials

The Alzheimer's Association announced in February 2026 that it would fund a Phase I safety and pharmacokinetics trial of CBG in early Alzheimer's disease patients, with enrollment expected to begin in late 2026. The trial will use a standardized CBG formulation developed by a consortium of academic medical centers and will include biomarker endpoints (CSF amyloid-beta, tau, and neuroinflammation markers) alongside safety and tolerability outcomes.

Context and Caution

Preclinical Alzheimer's research has a poor track record of translating to human benefit — over 99% of Alzheimer's drug candidates that succeeded in mouse models have failed in human trials. Researchers emphasized that these findings, while promising, do not establish that CBG will be effective in human Alzheimer's disease. The convergent findings from two independent groups using different models and methods are encouraging, but human trial data are essential before any clinical conclusions can be drawn.